Xaluprine (previously Mercaptopurine Nova Laboratories) (mercaptopurine)
- Region
- 🇪🇺 EU
- Active substance
- mercaptopurine
- Company
- Lipomed GmbH
- Status
- Authorised
- Therapeutic area
- Leukemia, Lymphoid
- CHMP opinion
- Thu 21 Jul 2011
- EU approval
- Fri 09 Mar 2012
- Application
- EMEA/H/C/002022
- ATC
- L01BB02
- Official record
- www.ema.europa.eu
Indication
Xaluprine is indicated for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Loulla Application withdrawn · Only For Children Pharmaceuticals
Follow Xaluprine (previously Mercaptopurine Nova Laboratories)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.